z-logo
Premium
Differential Transcription Factor Expression in Human Mononuclear Cells in Response to Amphotericin B: Identification with Complementary DNA Microarray Technology
Author(s) -
Cleary John D.,
Rogers P. David,
Chapman Stanley W.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.13.1046.34619
Subject(s) - biology , peripheral blood mononuclear cell , gene expression , gene , microarray analysis techniques , immune system , microbiology and biotechnology , amphotericin b , microarray , transcription (linguistics) , transcription factor , dna microarray , cell culture , in vitro , blot , immunology , genetics , antifungal , linguistics , philosophy
Study Objective. To identify genes differentially expressed in human monocytic cells exposed to amphotericin B in vitro. Design. In vitro experiment. Setting. Hospital laboratory. Material. Human mononuclear cell line, THP‐1. Intervention. Human mononuclear cells were exposed to amphotericin B or media alone for 6 hours. After exposure, total RNA was isolated and reverse transcribed to complementary DNA. Differences in probe hybridization observed during blotting were measured, and genes with altered regulation were described by using human complementary DNA microarray technology. Measurements and Main Results. Of 588 genes represented on the array, 16 transcripts were found to be upregulated and 4 transcripts were downregulated in response to amphotericin B. These findings suggest that amphotericin B alters the expression of genes in human monocytic cells that play a role in many cellular functions, including immune response, signal transduction, and cell differentiation. Conclusion. Amphotericin B induces alterations in human cell gene transcription. These changes could be used to evaluate differences in toxicity or efficacy observed in patients receiving this agent.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here